Zhitong Financial App News, Wuwu Biology (300357.SZ) issued an announcement. Recently, Zhejiang Wuwu Stem Cell Technology Co., Ltd. (hereinafter referred to as “Zhejiang Stem Cell”), an indirect holding subsidiary of the company, obtained the “Drug Clinical Trial Approval Notice” from the government service portal of the State Drug Administration, and the “Human Umbilical Cord Mesenchymal Stem Cell Type II Injection” (hereinafter referred to as “this product”) drug clinical trial application submitted by Zhejiang stem cells was approved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.